The reimbursement criteria may be published in the form as therapeutic indications and it is the prescriber`s responsibility to prescribe the drug to odB recipients according to the stated criteria. Product list agreements allow ODB recipients access to new drugs, while information that may support a future list is being collected and verified. Agreements on Ontario`s product lists should allow the province to tout the price of a drug in exchange for its inclusion in the provincial formula. The level and differences in the use of the ALP in Canadian provinces have the potential to have a significant impact on drug price consistency and access across the country. Currently, however, no province publishes information on the use of ALP for all funded drugs. This lack of public information on the use of GPs to date makes it difficult to participate in an informed debate on this political instrument in Canada. Several authors have collected information on the types of negotiated agreements that have been tried in one or more provinces (Carlson et al. 2010; Nason and Sproule 2011; Stafinski et al. 2010).
However, to our knowledge, no studies have systematically documented the use of ALP in Canada. We wanted to fill this gap in evidence by collecting information from all provinces on the use of ALP for a sample of drugs for which manufacturers have recently sought to cover themselves under provincial drug plans. Pathway Advisory Services has extensive transnational experience with many types of product list agreements and advises not only manufacturers, but also other consulting firms and provincial governments on how to deal with symbiotic product list agreements. We help our clients develop and challenge their promises of value (including their economic modeling), focusing on the simplicity and simplicity of their offering. We recognize that a simple analysis and implementation will significantly reduce the likelihood of a drug submission file being de-riorized, reducing the likelihood of costly delays that would prevent patients from accessing on time. It is equally important that we help our clients determine, through a detailed environmental scan, the promises of value that would be more attractive to their drug plan manager audience, so that customers can evaluate their product at an appropriate level that works well for both the public drug plan and their shareholders. More than ever, managers of national drug control programmes are overwhelmed with a recruitment perspective and are therefore forced to prioritize the time they can devote to a specific agreement on product list agreements. While this hierarchy is generally based on important factors such as perceived clinical needs and cost-effectiveness, it can nevertheless lead to the deseprisation of viable products, particularly when promises of value are considered less restrictive or require more time and resources in the pharmaceutical plan. The agreements aim to allow access to new and existing drugs under certain conditions and are based on a number of factors, including DCE recommendations, clinical evidence, therapeutic needs and cost-effectiveness. List agreements may include several elements: in return, a manufacturer was unable to sell a listed drug for the purpose of supplying a drug under the law at a price higher than its pharmaceutical advantage mentioned in the Form.